Asia FX moves little with focus on US-China trade, dollar steadies ahead of CPI
Investing.com -- Shares of Belluscura PLC (LON:BELLB), a UK-listed medical device company, plummeted 49.6% on Tuesday as investors reacted to the company's announcement regarding the potential impact of newly proposed US tariffs.
Belluscura, founded in the UK and headquartered in the U.S., has withdrawn its market guidance for the current year ending December 31, 2025, which was previously communicated on February 6, 2025.
The US Administration's announcement last week of a 54% tariff, up from the previous 20%, has compelled Belluscura to reassess its financial outlook.
The company, known for its oxygen enrichment technology, is facing a significant increase in tariffs for goods imported from China, where a considerable portion of its Portable Oxygen Concentrators, as well as raw materials and components, are manufactured.
This withdrawal indicates uncertainty about the company's future costs and its ability to maintain profitability in the face of rising import expenses.
The stock's sharp decline reflects investor concerns over the impact these tariffs will have on Belluscura's operations. With the increased tariffs, the company's cost of goods sold is expected to rise, potentially squeezing margins and affecting overall profitability.